Exagen (XGN) Preferred Stock Liabilities (2018 - 2019)

Exagen (XGN) posted Preferred Stock Liabilities of $121.0 million for Q2 2019, up 5.36% quarter-over-quarter from $114.9 million in Q1 2019.

Exagen (XGN) Preferred Stock Liabilities (2018 - 2019) Analysis & Trends

Exagen (XGN) has reported Preferred Stock Liabilities for 2 consecutive years, with $121.0 million the latest figure, recorded in Q2 2019.

Preferred Stock Liabilities for Q2 2019 came in at $121.0 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2019 was $121.0 million (changed N/A YoY), and the FY2018 annual result was $1.5 million, changed N/A from the prior year.
Preferred Stock Liabilities was $121.0 million for Q2 2019 at Exagen, up from $114.9 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $121.0 million in Q2 2019 and troughed at $1.5 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn	-
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn	-
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn	-
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn	-
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn	-
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn	-
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn	-
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn	-
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn	-
10	Exagen	112.36 Mn	90.84 Mn	10.21 Mn	-

Download Data